# A Study of TG103 Injection in Non-diabetic Overweight or Obesity

> **NCT05997576** · PHASE3 · COMPLETED · sponsor: **CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.** · enrollment: 675 (actual)

## Conditions studied

- Overweight or Obesity

## Interventions

- **DRUG:** TG103 22.5 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05997576
- **Lead sponsor:** CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-22
- **Primary completion:** 2025-02-17
- **Final completion:** 2025-03-03
- **Target enrollment:** 675 (ACTUAL)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05997576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05997576, "A Study of TG103 Injection in Non-diabetic Overweight or Obesity". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05997576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*